Tonix Pharmaceuticals stock halted ahead of FDA approval news
On Wednesday, Loop Capital analysts initiated coverage on Lionsgate Studios Corp (NASDAQ:LION) with a Hold rating and set a price target of $8.00. Trading at $7.28, the stock has shown strong momentum with a 9.15% gain over the past week. According to InvestingPro analysis, the stock appears slightly overvalued at current levels. The analysts cited the company’s current valuation and strategic position following its separation from Starz as key factors in their assessment.
Lionsgate, now a standalone entity, boasts a vast film and TV library with over 20,000 titles. InvestingPro data shows the company generates $3.2 billion in annual revenue, with a 7% growth rate. While this makes the company an attractive acquisition target, they carry a significant debt burden of nearly $4 billion. The analysts noted that management is currently focused on business growth rather than seeking acquisition opportunities.
The analysts highlighted that the company’s Board has put in place a 1-year poison pill, which could extend to three years if shareholders approve, as a defensive measure. This strategy underscores the company’s intent to concentrate on its internal growth initiatives.
Looking ahead, the analysts suggested that fiscal year 2026 would be a rebuilding period for Lionsgate, with expectations of lower backend profits compared to the previous year. While currently not profitable, InvestingPro analysis reveals analysts expect positive earnings of $0.39 per share in FY2026. The company anticipates fiscal year 2027 will benefit from improved results and a robust film schedule, including high-profile projects like the new installment in The Hunger Games franchise, a Michael Jackson biopic, and Mel Gibson’s The Resurrection of Christ.
The Hold rating reflects the analysts’ view that while Lionsgate is well-positioned in the market, its current valuation and strategic focus warrant a cautious approach for investors.
In other recent news, Raymond (NSE:RYMD) James initiated coverage on Lionsgate Studios Corp with an Outperform rating and set a price target of $10. The firm emphasized Lionsgate’s unique position as the only standalone public film and TV studio following its separation from Starz Entertainment. Despite a challenging fiscal year 2025, marked by box office disappointments and underperformance in the TV sector, Raymond James sees potential for growth. The analyst firm suggests that the current stock price reflects these setbacks, presenting an attractive entry point for investors. Looking forward, Lionsgate is expected to have a stronger lineup, which Raymond James predicts will drive significant revenue growth and operating income. Approximately half of the Motion Picture segment’s revenue and about 30% of total company revenues come from an existing content library, contributing to a more predictable cash flow. Raymond James also notes the possibility of Lionsgate becoming a target for acquisition by larger entities in Big Tech or Media. The firm’s analysis indicates that Lionsgate’s standalone success and potential for mergers and acquisitions make it an opportune time for investment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.